Comparison · NCT02586155-sae
High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: serious adverse events. Trial comparisons, record NCT02586155-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02586155-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.292 | 0.267 | 0.318 | wilson | |
| Risk in group 2 | 0.281 | 0.256 | 0.307 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0112 | -0.0248 | 0.0472 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.917 | 1.18 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.886 | 1.26 | log | |
| Number needed to harm, for one more participant with a serious adverse event on High-Intensity Statin Therapy+RVX000222 than on High-Intensity Statin Therapy+Placebo | 89.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | High-Intensity Statin Therapy+RVX000222 | Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)~Apabetalone: 100 mg capsule~Atorvastatin: High-Intensity Statin~Rosuvastatin: High-Intensity Statin | 354 | 1,212 | EG000 |
| Group 2 | High-Intensity Statin Therapy+Placebo | Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)~Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule~Atorvastatin: High-Intensity Statin~Rosuvastatin: High-Intensity Statin | 339 | 1,207 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 120 weeks
Source ClinicalTrials.gov
Trial
- Title
- Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
- NCT number
- NCT02586155
- Phases
- PHASE3
- Conditions
- Diabetes Mellitus, Type 2, Coronary Artery Disease
- Interventions
- Apabetalone, Placebo, Atorvastatin, Rosuvastatin
- Lead sponsor
- Resverlogix Corp
- Results first posted
- 2021-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02586155?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02586155-sae